Navigation Links
ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
Date:1/18/2008

e. Recent scientific research estimates that there are 3,800 asymptomatic vCJD carriers in the UK at a minimum and the 2006 National CJD Surveillance Unit report stated that "the incidence of vCJD may increase again, particularly if different genetic subgroups are found but with longer incubation periods".

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

About Pathogen Removal and Diagnostic Technologies Inc.

Pathogen Removal and Diagnostic Technologies Inc. ("PRDT") is a joint venture established in April 2002 by The American Red Cross and ProMetic Life Sciences Inc., and allows for the exchange of technology and knowledge between the two organizations. PRDT's main goal is to develop products and devices to remove and detect different pathogens from biological sources. This research augments work that ProMetic, the American Red Cross and PRDT's scientific founders have been conducting independently for many years.

About MacoPharma

MacoPharma (http://www.ma
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, owing to the launches ... market will increase more than sevenfold from $790 ... in the United States, France, Germany, Italy, Spain, ... Pharmacor report entitled Atrial Fibrillation finds ...
(Date:12/11/2009)... ROCKVILLE, Md., Dec. 11 EntreMed, Inc. ... of $1.7 million in royalty revenue from sales ... estimated royalty revenue of $3.3 million. In ... quarter and projected revenue for fiscal 2009. ... the third quarter will be reflected in the ...
(Date:12/11/2009)... have discovered a new explanation for differences in the severity ... a certain gene, the more serious the handicap. The genetic ... that it is the amount of copies of the GDI1 ... the American Journal of Human Genetics , and are ... connected to VIB, a life sciences research institute in Flanders, ...
(Date:12/11/2009)... ASA (OSE: ALGETA), the,cancer therapeutics company, announces ... the Tulane Cancer Center, New Orleans, has ... study of Alpharadin in men with,castration-resistant (also ... metastasized to the skeleton. , ... Prostate CAncer) study is a,double-blind, randomized, controlled ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2EntreMed Reports Receipt of Third Quarter Royalty Payment 2Amount of gene surplus determines severity of mental retardation in males 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... LAFAYETTE, Ind. - Fingerprints can reveal critical evidence, as ... new technology developed at Purdue University that detects trace ... in the prints. , The new technology also can ... a difficult task for current optical forensic methods. , ...
... University of Chicago scientists have induced electrons in the ... them into a smaller volume. This has the potential ... power. , "Slowing down the cooling of these electronsin ... a better infrared laser source," said Philippe Guyot-Sionnest, Professor ...
... Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... present a corporate update at the upcoming Lazard Capital ... to begin on Tuesday, November 18, 2008 at,9:25 a.m. ... Regis Hotel in New,York City November 18-19, 2008., ...
Other Biology Technology:Fingerprints provide clues to more than just identity 2New research expected to improve laser devices and make photovoltaics more efficient 2Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2
(Date:12/11/2009)... an associate professor of anthropology at the University of ... Kenya to understand how violence shapes the health of ... of her and her colleagues, research," Documenting the health ... northern Kenya: A conceptual framework," is currently published in ... , in collaboration with the British medical journal the ...
(Date:12/11/2009)... have traditionally been limited by the seasons, ... can be short. Thanks to researchers and ... introduced that offer growers the ability to ... bonuses for both producers and consumers. Fresh ... called "primocane-fruiting", which bear fruit on current-season ...
(Date:12/11/2009)... of Iowa researchers have found the existence of a ... on to find the genetic cause, which investigators hope ... The findings appeared in the Nov. 9 issue of ... located within the retina, is an area of high-resolution ... for example. This area is damaged in more common ...
Breaking Biology News(10 mins):UA-led study grapples with health effects of low-intensity warfare 2New management methods extend blackberry season 2New inherited eye disease discovered 2Teens May Not Benefit from Pap Tests 53010 1Teens May Not Benefit from Pap Tests 53010 2Teens May Not Benefit from Pap Tests 53010 3First genetically engineered malaria vaccine to enter human trials 9401 1First genetically engineered malaria vaccine to enter human trials 9401 2President Takes Illinois Womans Tough Health Care Questions at AARP Town Hall 53003 1President Takes Illinois Womans Tough Health Care Questions at AARP Town Hall 53003 2
... pinkish-purple ornamental flower, just patented by Cornell, can last for ... garden, it blooms all summer long in the cooler, northern ... new hybrid of the Inca lily ( Alstroemeria ), which ... that is set apart by its lavender-lilac flower color (which ...
... device designed to eliminate mistakes made while mixing compounds ... identifying the proper formulations of seven intravenous drugs. ... an 18-month period in a test at C.S. Mott ... by using the technology, said Jim Stevenson, associate dean ...
... Philadelphia, PA, January 8, 2008 The field of ... potential approaches to treatment. From the introduction of ... the U.S. Food and Drug Administration have had, at ... the dopamine D2 receptor. The introduction of clozapine ...
Other Biology News:Cornell patents a pink lily look-alike that blooms all summer long 2Device prevents potential errors in children's medications 2New treatment mechanisms for schizophrenia 2New treatment mechanisms for schizophrenia 3